Skip to main content
Back to Trials
NCT07346066PHASE3Recruiting

IS-001 Injection in Patients Undergoing Robotic-Assisted Colorectal Surgery

Intuitive Surgical

Start Date

5/14/2026

Completion Date

8/31/2027

Summary

This study evaluates the safety and efficacy of intravenous injection of IS-001 to aid in intraoperative ureter structure delineation

Detailed Description

Injury to the ureter, the duct by which urine passes from the kidney into the bladder, is a well-known and serious complication of pelvic and abdominal surgery that frequently goes unrecognized intraoperatively. This study seeks to evaluate the safety and efficacy of intravenous IS-001 injection to improve surgeon ureter visualization during robotic-assisted colorectal surgery with the da Vinci® Surgical System and Firefly® imaging.

Eligibility Criteria

Age Range: 16 years to 75 years

Inclusion Criteria: 1. Male and female participants between the ages of 16 and 75, inclusive 2. Participant is scheduled to undergo robotic-assisted colectomy using the da Vinci X/Xi Surgical System with SFF Fluorescence Imaging Exclusion Criteria 1\. Participant is pregnant or nursing 2. Participant has known current acute or chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection 3. Participant has any of the following screening laboratory values: eGFR \< 30 mL/min/1.73 m2 1. Aspartate aminotransferase (AST) ≥ 2.5 × ULN 2. Alanine aminotransferase (ALT) ≥ 2.5 × ULN 3. Total Bilirubin \> 2mg/dL 4. Participant has any concomitant non-colorectal cancer 5. Participant has any circumstances that, in the judgment of the Investigator, might make them not a suitable candidate for the study 6. Participants have already been enrolled in another investigational drug or device study within the past 6 months 7. Participants with known or suspected hypersensitivity to indocyanine green (ICG) or any components of the formulation used 8. Participant is expected to receive or has received other methods for ureter identification during the surgery (e.g., ureteral stent placement, illuminated catheters, retrograde ICG injections) before the administration of IS-001 9. The duration of the surgery is expected to be less than 90 minutes as determined during preoperative planning.

Interventions

DRUG

filricianine

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Ureter Injury

Locations

Hoag Memorial Hospital Presbyterian

Newport Beach, California 92663

United States

Yale New Haven Hospital

New Haven, Connecticut 06510

United States

Orlando Health

Orlando, Florida 32806

United States

Mountain View Hospital

Las Vegas, Nevada 89128

United States

The Ohio State Unversity

Columbus, Ohio 43210

United States

Kettering Health

Kettering, Ohio 45429

United States

St David's North Austin Medical Center

Austin, Texas 78758

United States

HCA Houston Healthcare Medical Center

Houston, Texas 77004

United States

MultiCare Tacoma General Hospital

Tacoma, Washington 98405

United States